PARP6 acts as a tumor suppressor via downregulating Survivin expression in colorectal cancer

Oncotarget

Volumn 7, Issue 14, 2016, Pages 18812-18824

  Qi, Guangying ^a,b   Kudo, Yasusei ^c   Tang, Bo ^a   Liu, Tian ^a   Jin, Shengjian ^a   Liu, Jing ^a   Zuo, Xiaoxu ^a   Mi, Sisi ^a   Shao, Wenhuan ^a   Ma, Xiaojuan ^a   Tsunematsu, Takaaki ^c   Ishimaru, Naozumi ^c   Zeng, Sien ^a   Tatsuka, Masaaki ^b   Shimamoto, Fumio ^b  

^a GUILIN MEDICAL UNIVERSITY   (China)

^b PREFECTURAL UNIVERSITY OF HIROSHIMA   (Japan)

^c UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Colorectal cancer; PARP6; Prognosis; Survivin; Tumor suppressor

Indexed keywords

NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 6; SURVIVIN; UNCLASSIFIED DRUG; BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; PARP6 PROTEIN, HUMAN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER PROGNOSIS; CANCER SURVIVAL; CELL GROWTH; CELL INVASION; CELL PROLIFERATION; COLONY FORMATION; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MIGRATION INHIBITION; MOUSE; NONHUMAN; ONCOGENE; PAPR6 GENE; PROTEIN EXPRESSION; SURVIVAL RATE; SURVIVIN GENE; TUMOR SUPPRESSOR GENE; UPREGULATION; COLORECTAL TUMOR; GENETICS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ADP RIBOSE TRANSFERASES; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DOWN-REGULATION; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MALE; SIGNAL TRANSDUCTION;

EID: 84975500428     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7712     Document Type: Article

References (32)

1. Klimczak A, Kempinska-Miroslawska B, Mik M, Dziki L, Dziki A. Incidence of colorectal cancer in Poland in 1999-2008 Arch Med Sci. 2011; 7:673-678.
2. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013; 49:1374-1403.
3. Chambon P, Weill JD, Mandel P. Nicotinamide mononucleotide activation of new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. Biochem Biophys Res Commun. 1963; 11:39-43.
4. Nishizuka Y, Ueda K, Nakazawa K, Hayaishi O. Studies on the polymer of adenosine diphosphate ribose. I. Enzymic formation from nicotinamide adenine dinuclotide in mammalian nuclei. J Biol Chem. 1967; 242:3164-3171.
5. Hsiao SJ, Smith S. Tankyrase function at telomeres, spindle poles, and beyond. Biochimie. 2008; 90:83-92.
6. Kraus WL: Transcriptional control by PARP-1. Chromatin modulation, enhancer-binding, coregulation, and insulation. Curr Opin Cell Biol. 2008; 20:294-302.
7. Kleine H, Poreba E, Lesniewicz K, Hassa PO, Hottiger MO, Litchfield DW, Shilton BH, Lüscher B. Substrate-assisted catalysis by PARP10 limits its activity to mono-ADPribosylation. Mol Cell. 2008; 32:57-69.
8. Hakme A, Wong HK, Dantzer F, Schreiber V. The expanding field of poly (ADP-ribosyl)ation reactions. 'Protein Modifications: Beyond the Usual Suspects' Review Series. EMBO Rep. 2008; 9:1094-1100.
9. Kim MY, Zhang T, Kraus WL. Poly(ADP-ribosyl)ation by PARP-1: 'PAR-laying' NAD+ into a nuclear signal. Genes Dev. 2005; 19:1951-1967.
10. Kraus WL. Transcriptional control by PARP-1: chromatin modulation, enhancer-binding, coregulation, and insulation. Curr Opin Cell Biol. 2008; 20:294-302.
11. Hassa PO, Hottiger MO. The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADPribose polymerases. Front Biosci. 2008; 13:3046-3082.
12. Schreiber V, Dantzer F, Ame JC, de Murcia G. Poly (ADPribose): novel functions for an old molecule. Nat Rev Mol Cell Biol. 2006; 7:517-528.
13. Goncalves A, Sabatier R, Charafe-Jauffret E, Gilabert M, Provansal M, Tarpin C, Extra JM, Viens P, Bertucci F. Triple-negative breast cancer: histoclinical and molecular features, therapeutic management and perspectives. Bull Cancer. 2013; 100:453-464.
14. Salemi M, Galia A, Fraggetta F, La Corte C, Pepe P, La Vignera S, Improta G, Bosco P, Calogero AE. Poly (ADPribose) polymerases 1 protein expression in normal and neoplastic prostatic tissue. Eur J Histochem. 2013; 57:13.
15. Porcelli L, Quatrale A E, Mantuano P, Leo MG, Silvestris N, Rolland JF, Carioggia E, Lioce M, Paradiso A, Azzariti A. Optimize radiochemotherapy in pancreatic cancer: PARP Inhibitors a new therapeutic opportunity. Mol Oncol. 2013; 7:308-322.
16. Kim J, Pyun J A, Cho S W, Lee K, Kwack K. Lymph node metastasis of gastric cancer is associated w ith the interaction between poly (ADP-ribose) polymerase 1 and matrix metallopeptidase 2. DNA Cell Biol. 2011; 30:1011-1017.
17. Tuncel H, Tanaka S, Oka S, Nakai S, Fukutomi R, Okamoto M, Ota T, Kaneko H, Tatsuka M, Shimamoto F. PARP6, a mono (ADP-ribosyl) transferase and a negative regulator of cell proliferation, is involved in colorectal cancer. Int J Oncol. 2012 41:2079-2086.
18. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997; 3:917-921.
19. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC. Control of apoptosis and mitotic spindle checkpoint by Survivin. Nature. 1998; 396:580-584.
20. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer. 2003; 3:46-54.
21. Tang B, Tang F, Lei B, Zeng S, Zhou L, He S, Kudo Y, Qi G. Expression of USP22 and Survivin is an indicator of malignant behavior in hepatocellular carcinoma. Int J Oncol. 2015; 47:2208-2216.
22. Qi G, Kudo Y, Ando T, Siriwardena B.S.M.S, Yoshida M, Keikahee MR, Ogawa I, Takata T. Nuclear Survivin expression is correlated with malignant behaviors of head and neck cancer together with Aurora-B. Oral Oncol. 2010; 46:263-270.
23. Qi G, Tuncel H, Aoki E, Tanaka S, Oka S, Kaneko I, Okamoto M, Tatsuka M, Nakai S, Shimamoto F. Intracellular localization of survivin determines biological behavior in colorectal cancer. Oncol Rep. 2009; 22:557-562.
24. Qi G, Ogawa I, Kudo Y, Miyauchi M, Siriwardena B.S.M.S, Shimamoto F, Tatsuka M, Takata T. Aurora-B expression and its correlation with cell proliferation and metastasis in oral cancer. Virchows Arch. 2007; 450:297-302.
25. Hori M, Miki T, Okamoto M, Yazama F, Konishi H, Kaneko H, Shimamoto F, Ota T, Temme A, Tatsuka M. The detergent-soluble cytoplasmic pool of survivin suppresses anoikis and its expression is associated with metastatic disease of human colon cancer. PLoS One. 2013; 8:e55710.
26. Tuncel H, Shimamoto F, Kaneko H, Aoki E, Jikihara H, Nakai S, Takata T, Tatsuka M. Nuclear Aurora B and cytoplasmic Survivin expression is involved in lymph node metastasis of colorectal cancer. Oncol Lett. 2012; 3:1109-1114.
27. Van Der Horst A, Lens SM. Cell division: control of the chromosomal passenger complex in time and space. Chromosoma. 2014; 123:25-42.
28. Yang D, Welm A, Bishop JM. Cell division and cell survival in the absence of Survivin. Proc Natl Acad Sci USA. 2004; 101:15100-15105.
29. Schreiber V, Dantzer F, Ame JC, de Murcia G. Poly(ADPribose): novel functions for an old molecule. Nat Rev Mol Cell Biol. 2006; 7:517-528.
30. Adida C, Haioun C, Gaulard P, Lepage E, Morel P, Briere J, Dombret H, Reyes F, Diebold J, Gisselbrecht C, Salles G, Altieri DC, Molina TJ. Prognostic signifiance of Survivin expression in diffuse large B-cell lymphomas. Blood. 2000; 96:1921-1925.
31. Ikeguchi M, Ueta T, Yamane Y, Hirooka Y, Kaibara N. Inducible nitric oxide synthase and Survivin messenger RNA expression in hepatocellular carcinoma. Clin Cancer Res. 2002; 8:3131-3136.
32. Yang D, Welm A, Bishop JM. Cell division and cell survival in the absence of Survivin. Proc Natl Acad Sci USA. 2004; 101:15100-15105.